Medipost Co (078160.KQ) Stock Price

Medipost Co Price

CLOSED
8,490.00
​
Market closed

Over the last 19 years Medipost Co grew revenue by 9.2% annually, reaching 73.66 B KRW. Earnings per share have grown at 0.0% per year over the last 16 years. For Medipost Co, the net margin of -115.9% is down versus -1.2% a few years ago.

Medipost Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medipost Co business model & stock analysis

Medipost Co., Ltd. generates revenue through the operation of cord blood banks, including public and family services. Public cord blood banks supply resources for hematopoietic stem cell transplantation for blood-related diseases like leukemia, while family cord blood banks store newborn cord blood exclusively for family use. The company also sells stem cell drugs for knee cartilage recovery and distributes healthcare food and natural cosmetics. Healthcare services are provided as part of their offerings. The primary buyers of public cord blood bank services are patients requiring HSCT for blood diseases, whereas family cord blood bank customers are parents storing cord blood for future family needs. Stem cell drugs target individuals seeking cartilage recovery treatments, and healthcare food and cosmetics are sold to consumers interested in wellness products. Healthcare services are utilized by clients seeking medical support. Medipost's product segments include cord blood storage, stem cell drugs, healthcare food, natural cosmetics, and healthcare services. The public cord blood bank serves medical institutions and patients, while family cord blood banks cater to families. Stem cell drugs and healthcare products target health-conscious consumers, and healthcare services support patients needing medical assistance.

Frequently asked questions about Medipost Co

Converted at the current exchange rate, the Medipost Co share trades at 5.65 EUR (8,490.00 KRW).

The expected revenue of Medipost Co is 82.90 B KRW. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medipost Co is -22.74 B KRW. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medipost Co is currently -14.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medipost Co stock.

The price-to-sales ratio (P/S) of Medipost Co is currently 4.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medipost Co stock.

The Eulerpool Quality Score for Medipost Co is 4/10.

The ISIN of Medipost Co is KR7078160009. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Medipost Co is 078160.KQ. The ticker symbol is used to trade Medipost Co shares on the stock exchange.

Fair ValueTerminal
8,065.50 KRW
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Providers & Services
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
South Korea
Currency
KRW
Initial public offering
Jul 29, 2005
ISIN
KR7078160009
Cusip
Y5905J106
Market capitalization
289.50 B KRWMega Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-14.59
P/S
P/Se
4.00
EV/EBIT
—
P/B Ratio
1.16
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-34.29 %
Last updated Nov 12, 2026, 1:22 AM

Medipost Co Peer Group

Medipost Co FIGI

078160:KS · BBG000F8XY22078160:KQ · BBG000F8XYW9